SANTA MONICA, CA, December 15, 2011 – Auritec Pharmaceuticals, Inc. announced today that it has entered into a Research Evaluation Agreement with a major pharmaceutical company (“Company”). Under the terms of the agreement, Auritec and the Company will collaborate on a research study which will test the performance of Auritec’s technology with a proprietary Company molecule.
Pharmena Hires Advisor To Help With Foreign Expansion
Pharmena, the manufacturer of innovative drugs and dermocosmetics listed on NewConnect, has appointed Destum Partners, a US consulting firm, to assist in finding business partners on foreign markets. The agreement, signed on 4 December, covers all markets worldwide except the United States and Canada. Under it, Destum will seek potential distributors or contract manufacturers of dermocosmetics produced by the Polish firm. The contract does not contain an exclusivity clause. Pharmena said it notified the stock market about the agreement because its huge territorial scope meant that it could have a major impact on the company’s revenues going forward.
Destum Partners Secures Partnership For Its Client Diamyd Medical With OMJPI
STOCKHOLM, SWEDEN, Tuesday, June 22, 2010 – Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy, The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd®) for the treatment and prevention of type 1 diabetes and associated conditions.